Pemetrexed Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0029 
Minor change in labelling or package leaflet not 
25/01/2024 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0026/G 
This was an application for a group of variations. 
13/10/2023 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
II/0025 
B.II.b.4.d - Change in the batch size (including batch 
28/09/2023 
n/a 
size ranges) of the finished product - The change 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
IA/0024/G 
This was an application for a group of variations. 
07/07/2023 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
IA/0023 
A.5.b - Administrative change - Change in the name 
17/02/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(excluding manufacturer for batch release) 
II/0020 
B.II.b.4.d - Change in the batch size (including batch 
13/10/2022 
n/a 
size ranges) of the finished product - The change 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
IA/0022 
B.II.e.2.a - Change in the specification parameters 
30/09/2022 
n/a 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/08/2022 
03/02/2023 
SmPC and PL 
Sections 4.4 and 4.6 of the SmPC have been updated 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
concerning duration of contraception following the end of 
treatment with a genotoxic drug, following assessment of 
the same changes adopted for the reference product. The 
package leaflet has been updated accordingly. 
IB/0019 
B.II.d.1.z - Change in the specification parameters 
23/05/2022 
n/a 
and/or limits of the finished product - Other variation 
IA/0018 
A.7 - Administrative change - Deletion of 
17/01/2022 
03/02/2023 
Annex II and 
manufacturing sites 
PL 
PSUSA/2330/
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
202102 
pemetrexed 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
29/07/2021 
27/01/2022 
PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IB/0015 
B.II.b.3.a - Change in the manufacturing process of 
04/06/2021 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/01/2021 
27/01/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
X/0010 
Annex I_2.(c) Change or addition of a new 
17/09/2020 
16/11/2020 
SmPC, 
strength/potency 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
Labelling and 
PL 
R/0012 
Renewal of the marketing authorisation. 
23/07/2020 
09/10/2020 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Pemetrexed Accord in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0013 
B.II.b.4.z - Change in the batch size (including batch 
14/08/2020 
n/a 
size ranges) of the finished product - Other variation 
IB/0011 
B.II.b.4.z - Change in the batch size (including batch 
06/05/2020 
n/a 
size ranges) of the finished product - Other variation 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/05/2019 
28/02/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0008 
B.II.b.2.a - Change to importer, batch release 
04/03/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0007/G 
This was an application for a group of variations. 
04/03/2019 
28/02/2020 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0006 
Transfer of Marketing Authorisation 
28/01/2019 
25/02/2019 
SmPC, 
Labelling and 
PL 
IB/0005 
C.I.z - Changes (Safety/Efficacy) of Human and 
20/04/2018 
25/02/2019 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/05/2017 
07/06/2018 
SmPC, 
generic/hybrid/biosimilar products following 
Labelling and 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
PL 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0003 
A.5.b - Administrative change - Change in the name 
14/09/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0002 
B.II.d.2.a - Change in test procedure for the finished 
03/08/2016 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0001 
B.II.e.3.b - Change in test procedure for the 
22/03/2016 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
